Tissue collected during the study indicated a mild rejection process had begun, requiring intensification of immunosuppression medication.
By “knocking out” the gene responsible for a biomolecule called alpha-gal – a prime target for roving human antibodies – the NYU Langone team were able to stop immediate rejection.
The donor pig in this experiment came from a herd cultivated by Virginia-based biotech company Revivicor.
The herd has also been approved by the Food and Drug Administration as a source of meat for people with hypersensitivity to the alpha-gal molecule, an allergy caused by some tick bites.
These pigs are bred, not cloned, meaning the process can be more easily scaled.
Early xenotransplantation research focused on harvesting organs from primates – for example, a baboon heart was transplanted into a newborn known as “Baby Fae” in 1984, but she survived only 20 days.
Current efforts focus on pigs, which are thought to be ideal donors for humans because of their organ size, their rapid growth and large litters, and the fact they are already raised as a food source.
In January 2022, surgeons at the University of Maryland Medical School carried out the world’s first pig-to-human transplant on a living patient – this time involving a heart.
He died two months after the milestone, with the presence of porcine cytomegalovirus in the organ later blamed.
Last week, Chinese scientists published a paper showing they had succeeded in hybrid pig-human kidneys in pig embryos, an alternative approach that also has the potential to one day help address organ donation shortages.
But the development raised ethical issues – especially since some human cells were also found in the pigs’ brains, experts said.
Source: CNA
